Sat, Dec 27, 2014, 2:11 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

  • fansteman fansteman Nov 25, 2013 11:40 AM Flag

    CLDX' vs. IMUC's GBM-programs

    People on this Board raised an interesting question: Any interference between these two programs? If so, how?

    CLDX' rindopepimut targets EGFRvIII-Marker+ patients, about 1/3 of all 1st-line GBM. It is a peptide vaccine, given intra-dermally. CLDX have an on-going trial in recurrent GBM, called reACT, and a 1st-line trial, called ACT IV. Both trials are actively recruiting. ACT IV is expected to be fully recruited by year end 2013, a first scheduled interim-analysis mid-2014, a second scheduled interim end of 2014. reACT was expanded based on the data presented at SNO. This trial has a tricky design: Group 1 is a randomization of bevacizumab (AVASTIN)-naive patients into rindo+GM-CSF+bev and "placebo"+bev while Group 2 gets rindo+GM-CSF+bev (all bev-failing patients).

    IMUC has two GBM-programs: ICT-107 is a dendritic cell vaccine given in conjunction with standard radio chemotherapy, applied intra-dermally, and is in Phase 2. The target patient population has to be HLA1/A2-positive, about 50-75% of 1st-line GBM. The trial completed recruitment in September 2012. Results are due any time now (CEO always speaks of Q4'13 or Q1'14). The company presented these spectacular Phase 1 long-term follow-up results on PFS and OS which seem to bode well for their Phase 2.

    Second IMUC GBM-program is with a CD133 targeted dendritic cell vaccine, ICT-121, in Phase 1, recruiting since mid-year, n=20, single-center. This target is particularly frequent in rec/ref GBM-patients, and the study is in 2nd-line patients only. I don't know (anybody?) whether also this trial is only in HLA1/A2-positive patients and whether that will be a selection criteria for further development and what the frequency of this biomarker is in 2nd-line GBM (same as 1st-line? different? how different?).

    Interferences?

    Target patient population: ICT-107 targets 50-75% of all 1st-line GBM patients. If their Phase 2 results are overwhelmingly positive and since they

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
IMUC
0.67-0.0100(-1.47%)Dec 26 4:01 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Rice Energy Inc.
NYSEFri, Dec 26, 2014 4:02 PM EST